Abstract:EGFR mutations are an ongoing challenge in the treatment of NSCLC, and demand continuous updating of EGFR TKI drug candidates. Pyrrolopyrimidines are one group of versatile scaffolds suitable for tailored drug development. However not many precedents of this type of pharmacophore have been investigated in the realm of third generation of covalent EGFR-TKIs. Herein, a series of pyrrolo[2,3-d]pyrimidine derivatives able to block mutant EGFR activity in a covalent manner were synthesized, through optimized Buchwald-Hartwig C-N cross coupling reactions. Their preliminary bioactivity and corresponding inhibitory mechanistic pathways were investigated at molecular and cellular levels. Several compounds exhibited increased biological activity and enhanced selectivity compared to the control compound. Notably, compound 12i selectively inhibits HCC827 cells harboring the EGFR activating mutation with up to 493-fold increased efficacy compared to in normal HBE cells. Augmented selectivity was also confirmed by kinase enzymatic assay, with the test compound selectively inhibiting the T790 M activating mutant EGFRs (IC50 values of 0.21 nM) with up to 104-fold potency compared to the wild-type EGFR (IC50 values of 22 nM). Theoretical simulations provide structural evidence of selective kinase inhibitory activity. Thus, this series of pyrrolo[2,3-dipyrimidine derivatives could serve as a starting point for the development of new EGFR-TKIs. (C) 2021 Elsevier Masson SAS. All rights reserved.

Novel potent and selective pyrazolylpyrimidine-based SYK inhibitors

Optimization of a series of potent, selective and orally bioavailable SYK inhibitors

Design and Synthesis of Novel Pyrrolo[2,3-D]pyrimidine Derivatives As Potent JAK3 and SYK Dual Inhibitors

Identification of a novel series of azabenzimidazole-derived inhibitors of spleen tyrosine kinase

Discovery of 3-(1H-benzo[d]imidazole-2-yl)-1h-pyrazol-4 -Amine Derivatives As Novel and Potent Syk Inhibitors for the Treatment of Hematological Malignancies.

Discovery of 6-[(3 S,4 S)-4-Amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-3-(2,3-dichlorophenyl)-2-methyl-3,4-dihydropyrimidin-4-one (IACS-15414), a Potent and Orally Bioavailable SHP2 Inhibitor

Identification of pyrazolopyridine derivatives as novel spleen tyrosine kinase inhibitors.

Design and optimization of orally spleen tyrosine kinase (SYK) inhibitors for treatment of solid tumor

Design, Synthesis and Evaluation of Pyrrolo[2,3-D]pyrimidine-phenylamide Hybrids As Potent Janus Kinase 2 Inhibitors.

Design, Synthesis, Biological Evaluation and Molecular Modeling of Novel 1H-Pyrazolo[3,4-d]pyrimidine Derivatives As BRAF(V600E) and VEGFR-2 Dual Inhibitors

Imidazo[1,2-b]pyridazines as inhibitors of DYRK kinases

Design, Synthesis and Activity Study of Pyridine Derivatives as Highly Effective and Selective TYK2 Inhibitors.

The Synthesis and Bioactivity of Pyrrolo[2,3-D]pyrimidine Derivatives As Tyrosine Kinase Inhibitors for NSCLC Cells with EGFR Mutations.

Synthesis and biological evaluation of novel 7-substituted 3-(4-phenoxyphenyl)thieno[3,2-c]pyridin-4-amines as potent Bruton's tyrosine kinase (BTK) inhibitors.

Discovery of Pyrazolo[1,5-a]pyrimidine TTK Inhibitors: CFI-402257 is a Potent, Selective, Bioavailable Anticancer Agent

Design, synthesis and biological evaluation of novel N-(methyl-d3) pyridazine-3-carboxamide derivatives as TYK2 inhibitors

Discovery of New Syk Inhibitors Through Structure-Based Virtual Screening.

Identification of 4-aminopyrazolylpyrimidines as potent inhibitors of Trk kinases.

Lead identification of novel and selective TYK2 inhibitors

Design, synthesis and evaluation of new pyrimidine derivatives as EGFRC797S tyrosine kinase inhibitors

Synthesis and Activity of New Aryl- and Heteroaryl-Substituted Pyrazole Inhibitors of the Transforming Growth Factor-Beta Type I Receptor Kinase Domain.